Liver toxicity caused by nevirapine

AIDS

Volumn 16, Issue 2, 2002, Pages 290-291

  González De Requena, Daniel ^a   Núñez, Marina ^a   Jiménez Nácher, Inmaculada ^a   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NEVIRAPINE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; PRIORITY JOURNAL;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER; NEVIRAPINE; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; TRANSAMINASES;

EID: 0037169260     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201250-00020     Document Type: Article

References (6)

1. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
2. Risk factors for severe liver toxicity following the introduction of HAART
3. Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: Correlation with CD4+ levels, hepatitis B & C seropositivity, and baseline liver function tests
4. Hepatic and cutaneous toxicity attributed to nevirapine
5. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
6. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection